REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-07-24. Anything still debated is marked as such rather than presented as settled.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
==== Deep vein thrombosis ==== DVT usually occurs in the veins of the legs, although it can also occur in the deep veins of the arms. Immobility, active cancer, obesity, traumatic damage and congenital disorders that make clots more likely are all risk factors for deep vein thrombosis. It can cause the affected limb to swell, and cause pain and an overlying skin rash. In the worst case, a deep vein thrombosis can extend, or a part of a clot can break off as an embolus and lodge in a pulmonary artery in the lungs, known as a pulmonary embolism. The decision to treat deep vein thrombosis depends on its size, symptoms, and their risk factors. It generally involves anticoagulation to prevents clots or to reduce the size of the clot. Intermittent pneumatic compression is a method used to improve venous circulation in cases of edema or in those at risk from a deep vein thrombosis.
== Veterinary medicine == Tramadol was the most common opioid prescribed by American veterinarians from 2014 to 2019; however, usage has declined in subsequent years due to more recent evidence suggesting that dogs do not metabolise tramadol into O-desmethyltramadol effectively. As metabolisation of tramadol relies on cytochrome P450 enzymes, it is species dependent and even individual genetics can have a profound impact on the efficacy of tramadol. A 2021 meta-analysis of tramadol use in dogs found that although tramadol was more effective than nalbuphine and codeine, it was less effective than methadone, COX inhibitors and multimodal analgesia with poor evidence to support the use of it is an analgesic for dogs. The mean alveolar concentration sparing effect of tramadol is negligible and with a high likelihood of rescue analgesia being required thus tramadol monotherapy is not recommended for the dog. One study looking at tramadol and meloxicam administered preoperatively provided no benefit compared to meloxicam given alone. Another study looking at cimicoxib versus tramadol for long-term post-operative pain following a tibial-plateau-levelling osteotomy found that although the level of analgesia was similar cimicoxib resulted in better mobility and a lower incidence of hock oedema. These studies and other evidence suggest that non-steroidal anti-inflammatory drugs provide superior analgesia to tramadol in dogs. Tramadol is more effective in cats although oral tramadol is poorly tolerated leading to low compliance.
Bâ Fatoumata Nènè Sy - former Minister of the Economy, Industry and Trade, Mali. Sy Maïmouna Ba - Minister of Agriculture, Livestock and the Environment, Mali. Mountaga Tall – Politician. former Minister, former First Vice-president of the National Assembly of Mali Diallo Sène - Former Minister for the Promotion of Women, Children, and the Family, Mali. Issaka Sidibé - President of The High Court, former president of The National Assembly. Sy Oumou Louise Sidibé - Former Minister of Public Health, Social Action and the Advancement of Women, Mali Bâ Odette Yattara - Former minister of women and children Affairs, Mali. Amadou Baba Sy - former Minister Of Mines. Cheick Diallo – NBA Basketball player. former New Orleans Pelicans player, Current Phoenix Suns player. USA, Mali Baréma Bocoum - Former minister of foreign affairs, Mali. Soumaré Aminata Sidibé - Former Minister of State Lands anFd Land Affairs of Mali. Ba Hawa Keïta - Former minister of labor and Vocational training, Mali. Michel Sidibe - physician, former Minister of Health And Social Welfare, former executive director UNAIDS. Boubou Cisse - Politician and economist. former prime minister and Minister of Economy and Finance; former Minister of Industry and Mines; Mali. Diallo Madeleine Bâ - Former Minister Of Health, Mali. Fanta Sylla - First Female Minister of Justice, Mali. Samba Ousemane Sow - Physician, former Minister Of Health. Diarra Mariam Flantié Diallo - former Minister of Communication and New Technologies. Diallo Sène - former Minister for the Promotion of Women, Children, and the Family.
== History == The journal was established in 1963 as Clinical Chemistry/Klinische Chemie. In 1991 it was renamed to European Journal of Clinical Chemistry and Clinical Biochemistry. In 1998 it obtained its present name.
or the coupling reagent COMU which is readily soluble as a dimethylmorpholine-uronium salt and which, like Oxyma, is superior to the standard additive HOBt for the suppression of racemization and acylation efficiency and is comparable to HOAt without presenting an explosion risk such as the benzotriazoles. With water-soluble derivatives of ethyl cyanohydroxyiminoacetate (glyceroacetonide-oxyma) as additive and DIC as coupling reagent even in weakly basic aqueous solutions the linking of protected amino acids to oligopeptides is possible with a yield of 95% and a diastereomeric excess of> 99% using the model substances Z-L-Phg-OH and L-H-Pro-NH2.
Sources: en.wikipedia.org
By 1902, sales made up 5 percent of the company's profits, and "heroinism" had attracted media attention. Oxycodone, a thebaine derivative similar to codeine, was introduced by Bayer in 1916 and promoted as a less-addictive analgesic. Preparations of the drug such as oxycodone with paracetamol and extended release oxycodone remain popular to this day. A range of synthetic opioids such as methadone (1937), pethidine (1939), fentanyl (late 1950s), and derivatives thereof have been introduced, and each is preferred for certain specialized applications. Nonetheless, morphine remains the drug of choice for American combat medics, who carry packs of syrettes containing 16 milligrams each for use on severely wounded soldiers. No drug has been found that can match the painkilling effect of opioids without also duplicating much of their addictive potential.
Biden entered office nine months into a recovery from the COVID-19 recession and his first year in office was characterized by robust growth in real GDP, employment, wages, and stock market returns, amid significantly elevated inflation. Real GDP grew 5.9%, the fastest rate in 37 years. Amid record job creation, the unemployment rate fell at the fastest pace on record. By the end of 2021, inflation rates measured by the consumer price index (CPI) reached a nearly 40-year high of 7.1%, which was partially offset by the highest nominal wage and salary growth in at least 20 years. The inflation rate peaked at 9% in June 2022. The inflation rate reached 2.9% and core inflation rate reached 3.2% on an annual basis in December 2024, the last full month of Biden's term. Between December 2020 and December 2024, CPI rose 21.3% overall, with an annualized inflation rate of 5.3% throughout Biden's term in office. The inflation rate remained above the Federal Reserve's 2% target every month since March 2021, resulting in elevated interest rates to combat inflation. Average wages increased 19% throughout Biden's presidency, falling behind inflation. The unemployment rate declined by over 2% and real GDP grew 11% during Biden's term. Total household net worth increased by 28%, largely driven by stocks and real estate. The national debt grew to $36.2 trillion, with a debt to GDP ratio of 123% and a deficit to GDP ratio of 6% in FY 2024. In February 2023, the unemployment rate fell to 3.4%, a 53-year low.
The two substrates of this enzyme are L-arogenic acid (shown as its conjugate base arogenate) and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are L-tyrosine, reduced NADH, and carbon dioxide. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-CH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is L-arogenate:NAD+ oxidoreductase (decarboxylating). Other names in common use include arogenic dehydrogenase (ambiguous), cyclohexadienyl dehydrogenase, pretyrosine dehydrogenase (ambiguous), and L-arogenate:NAD+ oxidoreductase. This enzyme participates in phenylalanine, tyrosine and tryptophan biosynthesis and novobiocin biosynthesis.
Out of this ₹11,000 crore (equivalent to ₹140 billion or US$1.5 billion in 2026) shall be utilized in promoting inland, marine fisheries, and aquacare and the remaining ₹9,000 crore (equivalent to ₹120 billion or US$1.2 billion in 2026) shall be deployed for building fishery infrastructure like harbors and cold storage chains. The government has targeted at increasing fish production to 700 thousand tonnes and help increase India's export to 1 trillion. The financial aid is also intended to provide employment opportunities to 5.5 million people in the next five years.
== Interactions == Concurrent use with other triptans or ergot-containing medications (e.g., ergotamine, dihydroergotamine) within 24 hours can result in additive vasoconstriction. Increased systemic exposure to sumatriptan can occur if used within 2 weeks after a monoamine oxidase inhibitor (MAOI). Cases of serotonin syndrome have been reported with co-administration of triptans and serotonin reuptake inhibitors.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.